Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naĂŻve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)
Back

Dupilumab for the Treatment of Chronic Spontaneous Urticaria in Patients Who Remain Symptomatic Despite the Use of H1 Antihistamine and Who Are naĂŻve to, Intolerant of, or Incomplete Responders to Omalizumab (LIBERTY-CSU CUPID)

Completed

Open to: ALL

Age: 6.0 - 80.0

London Manchester

Medical Conditions

Urticaria
Chronic Urticaria

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


Primary Objective:

To demonstrate the efficacy of dupilumab in study participants with CSU who remain symptomatic despite the use of H1 antihistamine (Study A and C: omalizumab naĂŻve; Study B: omalizumab intolerant or incomplete responders)

Secondary Objectives:

To demonstrate the efficacy of dupilumab on urticaria activity composite endpoint and itch or hives, separately, at various timepoints To demonstrate the efficacy of dupilumab on angioedema To demonstrate the efficacy of dupilumab on urticaria control To demonstrate improvement in health-related quality of life and overall disease status and severity To evaluate the ability of dupilumab in reducing the proportion of patients who require treatment with oral corticosteroids (OCS) To evaluate safety outcome measures To evaluate immunogenicity of dupilumab

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Dec 2019 Aug 2024

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Pharmaceutical form:Injection solution Route of administration: Subcutaneous

Intervention Arm Group : Study A Dupilumab;Study B Dupilumab;Study C Dupilumab;

Intervention Type : DRUG
Intervention Description : Pharmaceutical form:Injection solution Route of administration: Subcutaneous

Intervention Arm Group : Study A Matched Placebo;Study B Matched Placebo;Study C Matched Placebo;

Intervention Type : DRUG
Intervention Description : Pharmaceutical form:Tablet Route of administration: oral administration

Intervention Arm Group : Study A Dupilumab;Study A Matched Placebo;Study B Dupilumab;Study B Matched Placebo;Study C Dupilumab;Study C Matched Placebo;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Investigational Site Number : 8260002
    London
    London, City Of
    E1 1BB
  • Investigational Site Number : 8260001
    Manchester
    M23 9QZ,


The study is sponsored by Sanofi and is in collaboration with Regeneron Pharmaceuticals.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT04180488
Last updated 10 December 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top